Overview
Background
Maher Gandhi received his medical degree in the UK in 1989, and then trained as a haematologist, including a Fellowship in malignant haematology at Princess Margaret Cancer Centre, Toronto. He was awarded a PhD in immunology at Cambridge University under Patrick Sissons. He moved to Brisbane and from 2003-2024 worked as a Senior Staff Specialist (Pre-Eminent Status) in the Haematology / Oncology Department of the Princess Alexandra Hospital. He leads his own laboratory group and has established an international reputation studying the tumour immune microenvironment in lymphoma and its manipulation, with continuous NHMRC/MRFF funding since 2005. He was Chair of Laboratory Sciences for the Australasian Leukaemia and Lymphoma Group between 2010-2016, won the prestigious Australian Society of Medical Research Clinical Research Award in 2010 and in 2012 took up the inaugural John McCaffrey Cancer Council of Queensland / Office of Health and Medical Research Clinical Research Fellowship. Between 2011-2014 he was privileged to serve as Chair of the Metro South Human Research Ethics Committee. In 2013 he was appointed Professor of Experimental Haematology, University of Queensland, based at the Translational Research Institute, in 2014 became the inaugural Leukaemia Foundation Chair of Blood Cancer Research at the University of Queensland Frazer Institute, and was appointed Cancer Program Head in 2016. In 2018 he became Executive Director and Director of Clinical Research at Mater Research. He also continues to head the Blood Cancer Research Group, which is based in Mater Research. In 2025 to current, he was appointed Chief Executive Officer of the Translational Research Institute and its manufacturing branch TM@TRI, to serve Queenslanders by transforming health through collaborative research.
Availability
- Professor Maher Gandhi is:
- Available for supervision
- Media expert
Fields of research
Qualifications
- Bachelor of Medicine Surgery, University of Aberdeen
- Doctor of Philosophy, University of Cambridge
Research interests
-
Lymphoma
-
Immunotherapy
-
Biomarkers
Research impacts
The research of the Blood Cancer Research Laboratory aims to understand the basis of lymphoma; to devise new treatments which are less toxic and more effective; to establish new biomarkers which will help determine the most effective treatment strategies and to monitor response and relapse and understand the development of lymphomas. The group has a strong emphasis on patient material, which it obtains from international and national clinical collaborators. Lymphomas studied includeEBV-associated lymphomas, Hodgkin Lymphoma, PTLD, Diffuse Large B-cell Lymphoma, Follicular Lymphoma and amyloidosis. We utilise a broad range of approaches including genomics, transcriptomics and functional immunoassays, and are conducting a number of MRFF funded cellular therapy studies sponsored by the Australasian Leukaemia and Lymphoma Group.
The Mater Foundation, the Leukaemia Foundation, the Mark Coghlan EBV Lymphoma Project and the Brisbane Girls Grammar School Kirsten Jack Memorial Fund are thanked for their kind support.
Works
Search Professor Maher Gandhi’s works on UQ eSpace
2021
Journal Article
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience
Lewis, Katharine L., Chin, Collin K., Manos, Kate, Casey, John, Hamad, Nada, Crawford, Julie, Ho, Shir-Jing, Issa, Samar, Grigg, Andrew, Wood, Peter, Gandhi, Maher K., Do, Bryan, Nastoupil, Loretta, Hawkes, Eliza A. and Cheah, Chan Y. (2021). Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. British Journal of Haematology, 192 (6) bjh.16946, 1049-1053. doi: 10.1111/bjh.16946
2021
Journal Article
Targeted treatment of follicular lymphoma
Nath, Karthik and Gandhi, Maher K. (2021). Targeted treatment of follicular lymphoma. Journal of Personalized Medicine, 11 (2) 152, 1-22. doi: 10.3390/jpm11020152
2021
Book Chapter
Host genetic mutations and expression analyses in PTLD
Lees, Charlotte and Gandhi, Maher K. (2021). Host genetic mutations and expression analyses in PTLD. Post-transplant lymphoproliferative disorders. (pp. 39-50) edited by Vikas R. Dharnidharka, Michael Green, Steven A. Webber and Ralf Ulrich Trappe. Cham, Switzerland: Springer . doi: 10.1007/978-3-030-65403-0_4
2021
Journal Article
A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma
Tobin, Joshua W. D., Crothers, Anna, Ma, Ti Eric, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. Leukemia and Lymphoma, 62 (14), 1-9. doi: 10.1080/10428194.2021.1957866
2021
Journal Article
Tumor microenvironment of follicular lymphoma
Nath, Karthik, Tsang, Hennes and Gandhi, Maher K. (2021). Tumor microenvironment of follicular lymphoma. Annals of Lymphoma, 5, 1-19. doi: 10.21037/aol-20-55
2020
Journal Article
Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment
Kobayashi, Takumi, Lam, Pui Yeng, Jiang, Hui, Bednarska, Karolina, Gloury, Renee Elyse, Murigneux, Valentine, Tay, Joshua, Jacquelot, Nicolas, Li, Rui, Tuong, Zewen Kelvin, Leggatt, Graham, Gandhi, Maher K., Hill, Michelle M, Belz, Gabrielle T., Ngo, Shyuan, Kallies, Axel and Mattarollo, Stephen R. (2020). Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment. Blood, 136 (26), 3004-3017. doi: 10.1182/blood.2020005602
2020
Conference Publication
A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma
Tobin, Joshua W.D., Hapgood, Greg, Gandhi, Maher K., Mollee, Peter, Ma, Ti, Crothers, Anna and Scuffham, Paul (2020). A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2020-138590
2020
Conference Publication
Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma
Tsang, Hennes, Patch, Ann-Marie, Keane, Colm, Law, Soi C., Gunawardana, Jay, Blombery, Piers, Thompson, Ella R., Sabdia, Muhammed B., De Long, Lilia Merida, Belle, Clemence J., Nath, Karthik, Tobin, Joshua W.D., Kazakoff, Stephen H., Seymour, John F., MacManus, Michael and Gandhi, Maher K. (2020). Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-135954
2020
Journal Article
DA-EPOCH-R in Burkitt Lymphoma: Is it enough for high-risk disease?
Hertzberg, Mark, Joske, David J. L. and Gandhi, Maher K. (2020). DA-EPOCH-R in Burkitt Lymphoma: Is it enough for high-risk disease?. Journal of Clinical Oncology, 38 (31), 3722-3723. doi: 10.1200/jco.20.01850
2020
Journal Article
Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma
Gunawardana, Jay, Lee, Justina N., Bednarska, Karolina, Murigneux, Valentine, Long, Lilia Merida, Sabdia, Muhammed B., Birch, Simone, Tobin, Joshua W. D. and Gandhi, Maher K. (2020). Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma. eJHaem, 1 (2) jha2.116, 517-526. doi: 10.1002/jha2.116
2020
Journal Article
Risk‐adapted therapy in follicular lymphoma: is it time to FLEX ?
Tobin, Joshua W. D. and Gandhi, Maher K. (2020). Risk‐adapted therapy in follicular lymphoma: is it time to FLEX ?. American Journal of Hematology, 95 (12) ajh.26016, 1454-1456. doi: 10.1002/ajh.26016
2020
Journal Article
Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphoma
Bararia, Deepak, Hildebrand, Johannes A., Stolz, Sebastian, Haebe, Sarah, Alig, Stefan, Trevisani, Christopher P., Osorio-Barrios, Francisco, Bartoschek, Michael D., Mentz, Michael, Pastore, Alessandro, Gaitzsch, Erik, Heide, Michael, Jurinovic, Vindi, Rautter, Katharina, Gunawardana, Jay, Sabdia, Muhammed B., Szczepanowski, Monika, Richter, Julia, Klapper, Wolfram, Louissaint, Abner, Ludwig, Christina, Bultmann, Sebastian, Leonhardt, Heinrich, Eustermann, Sebastian, Hopfner, Karl-Peter, Hiddemann, Wolfgang, von Bergwelt-Baildon, Michael, Steidl, Christian, Kridel, Robert ... Weigert, Oliver (2020). Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphoma. Cell Reports, 31 (5) 107522, 107522. doi: 10.1016/j.celrep.2020.107522
2020
Journal Article
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma
Keane, Colm, Law, Soi C., Gould, Clare, Birch, Simone, Sabdia, Muhammed B., Merida de Long, Lilia, Thillaiyampalam, Gayathri, Abro, Emad, Tobin, Joshua W., Tan, Xiaohong, Xu-Monette, Zijun Y., Young, Ken H., Gifford, Grace, Gabreilli, Sara, Stevenson, William S., Gill, Anthony, Talaulikar, Dipti, Jain, Sanjiv, Hernandez, Annette, Halliday, Sarah-Jane, Bird, Robert, Cross, Donna, Hertzberg, Mark and Gandhi, Maher K. (2020). LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Advances, 4 (7), 1367-1377. doi: 10.1182/bloodadvances.2019001390
2020
Journal Article
Reply to M. Sorigue
Tobin, Joshua W.D., Keane, Colm, Gunawardana, Jay and Gandhi, Maher K. (2020). Reply to M. Sorigue. Journal of Clinical Oncology, 38 (6), 648-649. doi: 10.1200/JCO.19.02935
2020
Journal Article
Targeting an adenosine-mediated “don’t eat me signal” augments anti-lymphoma immunity by anti-CD20 monoclonal antibody
Nakamura, Kyohei, Casey, Mika, Oey, Harald, Vari, Frank, Stagg, John, Gandhi, Maher K. and Smyth, Mark J. (2020). Targeting an adenosine-mediated “don’t eat me signal” augments anti-lymphoma immunity by anti-CD20 monoclonal antibody. Leukemia, 34 (10), 2708-2721. doi: 10.1038/s41375-020-0811-3
2019
Conference Publication
Intra-tumoral CD8+T-cells in follicular lymphoma contain large clonal expansions that are amenable to dual-checkpoint blockade
Nath, Karthik, Law, Soi C., Sabdia, Muhammed B., De Long, Lilia Merida, Shanavas, Mohamed, Tobin, Joshua W. D., Gunawardana, Jay, Vari, Frank, Halliday, Sarah-Jane, Hernandez, Annette, Cross, Donna, Bird, Robert J., Keane, Colm and Gandhi, Maher K. (2019). Intra-tumoral CD8+T-cells in follicular lymphoma contain large clonal expansions that are amenable to dual-checkpoint blockade. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando, FL, United States, 7 - 10 December 2019. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood-2019-130050
2019
Journal Article
EBV-microRNA-BHRF1-2-5p targets the 3'UTR of immune-checkpoint ligands PD-L1 and PD-L2
Cristino, Alexandre S., Nourse, Jamie, West, Rachael A., Sabdia, Muhammed Bilal, Law, Soi C., Gunawardana, Jay, Vari, Frank, Mujaj, Sally, Thillaiyampalam, Gayathri, Snell, Cameron, Gough, Madeline, Keane, Colm and Gandhi, Maher K. (2019). EBV-microRNA-BHRF1-2-5p targets the 3'UTR of immune-checkpoint ligands PD-L1 and PD-L2. Blood, 134 (25), 2261-2270. doi: 10.1182/blood.2019000889
2019
Journal Article
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance
Tobin, Joshua W. D., Rule, Gabrielle, Colvin, Katherine, Calvente, Lourdes, Hodgson, David, Bell, Stephen, Dunduru, Chengetai, Gallo, James, Tsang, Erica S., Tan, Xuan, Wong, Jonathan, Pearce, Jessica, Campbell, Robert, Tneh, Shao, Shorten, Sophie, Ng, Melissa, Cochrane, Tara, Tam, Constantine S., Abro, Emad, Hawkes, Eliza, Hodges, Georgina, Kansara, Roopesh, Talaulikar, Dipti, Gilbertson, Michael, Johnston, Anna M., Savage, Kerry J., Villa, Diego, Morris, Kirk, Ratnasingam, Sumi ... Hapgood, Greg (2019). Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Advances, 3 (19), 2804-2811. doi: 10.1182/bloodadvances.2019000458
2019
Journal Article
The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma
Keane, Colm, Tobin, Joshua, Gunawardana, Jay, Francis, Santiyagu, Gifford, Grace, Gabrielli, Sara, Gill, Anthony, Stevenson, William, Talaulikar, Dipti, Gould, Clare, Jain, Sanjiv, Birch, Simone, Hertzberg, Mark and Gandhi, Maher K. (2019). The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma. European Journal of Haematology, 103 (3) ejh.13274, 200-207. doi: 10.1111/ejh.13274
2019
Journal Article
Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration
Tobin, Joshua W. D., Keane, Colm, Gunawardana, Jay, Mollee, Peter, Birch, Simone, Hoang, Thanh, Lee, Justina, Li, Li, Huang, Li, Murigneux, Valentine, Fink, J. Lynn, Matigian, Nicholas, Vari, Frank, Francis, Santiyagu, Kridel, Robert, Weigert, Oliver, Haebe, Sarah, Jurinovic, Vindi, Klapper, Wolfram, Steidl, Christian, Sehn, Laurie H., Law, Soi-Cheng, Wykes, Michelle N. and Gandhi, Maher K. (2019). Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration. Journal of Clinical Oncology, 37 (34), 3300-3309. doi: 10.1200/JCO.18.02365
Funding
Current funding
Supervision
Availability
- Professor Maher Gandhi is:
- Available for supervision
Looking for a supervisor? Read our advice on how to choose a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Metabolic Reprogramming of Malignant B-cells Impairs Immune-Fitness of Intratumoral T-Cells in Follicular Lymphoma
Principal Advisor
Other advisors: Dr Joshua Tobin, Dr Soi Law
-
Doctor Philosophy
The role of neoantigen targeted immunity in Chronic Lymphocytic Leukaemia
Principal Advisor
Other advisors: Honorary Professor Kristen Radford, Associate Professor Adam Ewing
-
Doctor Philosophy
Development of novel vaccines for cancer immunotherapy
Associate Advisor
Other advisors: Associate Professor Kelvin Tuong, Honorary Professor Kristen Radford
-
Doctor Philosophy
Designer Cytokine Profiling to Overcome Immunometabolic Barriers to Allogenic Cellular Therapies in Haematological Malignancy
Associate Advisor
Other advisors: Dr Soi Law, Dr Joshua Tobin
-
Doctor Philosophy
Investigations in the development of cord blood derived, GMP grade cellular immunotherapies
Associate Advisor
Other advisors: Honorary Professor Kristen Radford
-
Doctor Philosophy
Impact of genetics upon the tumour microenvironment in Follicular Lymphoma
Associate Advisor
Other advisors: Dr Soi Law, Associate Professor Colm Keane, Dr Joshua Tobin
-
Master Philosophy
Developing Companion Biomarkers Application in Follicular Lymphoma
Associate Advisor
Other advisors: Associate Professor Adam Ewing, Dr Joshua Tobin
Completed supervision
-
2022
Doctor Philosophy
A Comprehensive Study of Intratumoural T-cells in Follicular Lymphoma
Principal Advisor
Other advisors: Dr Soi Law, Associate Professor Colm Keane
-
2021
Doctor Philosophy
Clinical and Prognostic Tools to Improve Frontline Management Strategies in Follicular Lymphoma
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
2020
Doctor Philosophy
The impact of deficient antigen presentation on the tumour microenvironment of diffuse large B cell lymphoma
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
-
2019
Doctor Philosophy
A LABORATORY STUDY OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
2016
Master Philosophy
Killer cell Immunoglobulin-like Receptors in Immune Thrombocytopenia (ITP)
Principal Advisor
-
2013
Doctor Philosophy
Novel strategies for monitoring, treating and preventing Epstein Barr virus-associated Lymphomas
Principal Advisor
-
2020
Doctor Philosophy
Characterising miRNA - gene network associated with natural killer cell activation
Associate Advisor
Other advisors: Dr Soi Law
-
2019
Doctor Philosophy
Deciphering the structure and function of class I cytokine receptors: GHR and GP130
Associate Advisor
-
2013
Doctor Philosophy
IRE1-mediated splicing of xbp1 in Natural Killer cells
Associate Advisor
Media
Enquiries
Contact Professor Maher Gandhi directly for media enquiries about:
- Biomarkers
- Immunotherapy
- Lymphoma
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: